Heron Therapeutics, Inc.

NASDAQ:HRTX

Biotechnology

Healthcare
$0.27 +3.74%

+$0.01 today

Market cap
$51.94M
Beta
1.57
P/E (TTM)
-2.5
EPS (TTM)
-$0.16
52W Low $0.38High $2.30

Volume 1.81M

Average 2.90M

HRTX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Heron Therapeutics, Inc.NASDAQ: HRTX

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $2.98M rose 18.5% year over year, ahead of the -10.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 36.6% from the prior quarter. Over 3 fiscal years it compounded at -37.8% a year.

Context

  • Stock-based compensation amounted to 6.7% of revenue in FY2025, down 2.3 pp from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +18.5% holds above the trailing-twelve-month pace of -10.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.98M+36.6% QoQ
Last fiscal yearDec 2025
$10.34M-20.2% YoY
LTMMar 2026
$10.8M-10.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.5%——
1 year-20.2%——
3-year CAGR-37.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
10.34M USD
Year-over-year change
-20.2%
4-year CAGR
-31.5%

Stock-Based Compensation vs competitors

How HRTX compares with its peers on the latest reported figures

  • HRTX's LTM Mar 2026 stock-based compensation of $10.8M is the 5th largest of the 10 companies compared; the peer median is $4.36M.
  • Its year-over-year change of -10.7% is the 3rd highest of 9, against a peer median of -20.5%.
  • Stock-based compensation amounts to 7.2% of revenue for HRTX, versus a peer median of 20.6%.
HRTX Competitors Peer median
Stock-Based Compensation for HRTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CHRSCoherus Oncology, Inc.LTM Mar 2026$21.99M -15.0%-30.6%46.9%
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$15.21M ———
OABIOmniAb, Inc.LTM Mar 2026$15.02M -24.7%-4.8%52.0%
IVVDInvivyd, Inc.LTM Mar 2026$11.51M -33.2%-18.7%20.6%
HRTXHeron Therapeutics, Inc.LTM Mar 2026$10.8M -10.7%-37.8%7.2%
TARAProtara Therapeutics, Inc.LTM Mar 2026$4.36M +16.7%-17.0%—
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$4.19M +122.7%+4.3%—
MDWDMediWound Ltd.LTM Mar 2026$2.91M -16.2%+16.9%20.1%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$1.44M -63.8%——
PLXProtalix BioTherapeutics, Inc.LTM Mar 2026$8K -100.3%+3.3%0.0%
Peer median (excluding HRTX) $4.36M-20.5%-4.8%20.6%

Competitors are the stored peer set for HRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(220.68M)(182.02M)(110.56M)(13.58M)(20.2M)
Depreciation & Amortization3.02M2.89M2.9M2.49M2.31M
Deferred Income Tax1.63M0000
Stock-Based Compensation46.85M42.98M32.85M12.96M10.34M
Change in Working Capital(35.08M)(10.51M)16.79M(27.6M)(31.88M)
Accounts Receivables6.35M(16.55M)(8.09M)(18.74M)(10.71M)
Inventory(6.48M)(6.19M)12.46M(11.05M)(31.05M)
Accounts Payables3.28M(578K)15K8.47M(2.72M)
Other Working Capital(38.23M)12.81M12.4M(6.28M)12.59M
Other Non-Cash Items904K(251K)(773K)3.2M11.83M
Operating Cash Flow(203.35M)(146.91M)(58.79M)(22.53M)(27.59M)
Capital Expenditures(3.02M)(1.83M)(1.55M)(1.71M)(317K)
Acquisitions (Net)32K227K13K27K0
Purchases of Investments(129.22M)(145.68M)(87.66M)(103.09M)(50.79M)
Sales of Investments164.94M143.96M107.19M123.48M67.01M
Other Investing Activities000098K
Investing Cash Flow32.73M(3.32M)18M18.71M16.01M
Debt Repayment148.96M024.35M0145.11M
Common Stock Issued7.07M75.06M29.76M940K19.32M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0000(150M)
Financing Cash Flow156.03M75.06M54.11M940K14.43M
Effect of Forex Changes00000
Net Change in Cash(14.6M)(75.18M)13.31M(2.88M)2.85M
Free Cash Flow(206.38M)(148.74M)(60.33M)(24.24M)(27.91M)

Heron Therapeutics, Inc.

NASDAQ:HRTX

Intrinsic Alpha fair value

Locked

Current Price

$0.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.